APA (7th ed.) Citation

Tasaki, Y., Ito, N., Mimura, Y., Sugiyama, Y., Ogawa, R., Shimura, T., . . . Iwasaki, S. (2024). Real‐world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients. Asia Pacific Journal of Clinical Oncology, 20(4), 515. https://doi.org/10.1111/ajco.14073

Chicago Style (17th ed.) Citation

Tasaki, Yoshihiko, et al. "Real‐world Data on Efficacy/safety and Economic Impact of Nivolumab Administered Every 2 and 4 weeks Among Japanese Patients." Asia Pacific Journal of Clinical Oncology 20, no. 4 (2024): 515. https://doi.org/10.1111/ajco.14073.

MLA (9th ed.) Citation

Tasaki, Yoshihiko, et al. "Real‐world Data on Efficacy/safety and Economic Impact of Nivolumab Administered Every 2 and 4 weeks Among Japanese Patients." Asia Pacific Journal of Clinical Oncology, vol. 20, no. 4, 2024, p. 515, https://doi.org/10.1111/ajco.14073.